|Articles|October 1, 2007

Postle fig 6

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Pfizer’s current position reflects a misalignment. Its science is credible, its scale is unmatched, but its story is still forming. Until that story becomes clear and compelling, the valuation gap may persist. Credit: Stock.Adobe.com/Kathy images.

Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff

ByThani Jambulingam, PhD

April 20th 2026

Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics

ByNicholas Jacobus

April 20th 2026

President Trump Signs Executive Order to Accelerate FDA Reviews for Psychedelic Drugs

ByNicholas Jacobus

April 20th 2026

Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics

ByNicholas Jacobus

April 20th 2026

Addressing Regulatory Issues and the Biosimilar Void: Q&A with Thomas Newcomer

ByMike Hollan,Thomas Newcomer

April 20th 2026

Postle fig 6

Newsletter

Related Content

Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff

Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics

President Trump Signs Executive Order to Accelerate FDA Reviews for Psychedelic Drugs

Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics

Addressing Regulatory Issues and the Biosimilar Void: Q&A with Thomas Newcomer

Trending on PharmExec

Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics

President Trump Signs Executive Order to Accelerate FDA Reviews for Psychedelic Drugs

Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff

Addressing Regulatory Issues and the Biosimilar Void: Q&A with Thomas Newcomer

Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning